 "Note: Figures for 9M FY 2017; (sales contribution of US business of DRL was 50.7% in FY16)")
Pricing pressure and regulatory issues are not the only thing worrying executives of Indian pharmaceuticals companies.
Weakening of the dollar versus the rupee in the first four months of this calendar year is adding to the concerns; it might impact their earnings by five or six per cent. An appreciation in the rupee versus the dollar means every one of the latter yields less of the former, whereas a lot of the costs are denominated in rupees. Dr Reddy’s Laboratories (DRL), Lupin and Sun Pharmaceutical earn close to half their revenue from the US market. DRL has the highest
Weakening of the dollar versus the rupee in the first four months of this calendar year is adding to the concerns; it might impact their earnings by five or six per cent. An appreciation in the rupee versus the dollar means every one of the latter yields less of the former, whereas a lot of the costs are denominated in rupees. Dr Reddy’s Laboratories (DRL), Lupin and Sun Pharmaceutical earn close to half their revenue from the US market. DRL has the highest
